Relmada Therapeutics, Inc. stock is down -19.34% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 44.44% of the previous 8 December’s closed higher than November. In the last 1 Unusual Options Trades, there were 1 CALL.
Relmada Therapeutics, Inc. focuses on developing various products for the treatment of central nervous system diseases and other disorders. The company was founded in 2004 and is headquartered in Coral Gables, Florida. Its lead product candidate is Esmethadone, a new chemical entity and N-methyl-D-aspartate receptor antagonist.